Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

David L Thomas, Chloe L Thio, Maureen P Martin, Ying Qi, Dongliang Ge, Colm O'Huigin, Judith Kidd, Kenneth Kidd, Salim I Khakoo, Graeme Alexander, James J Goedert, Gregory D Kirk, Sharyne M Donfield, Hugo R Rosen, Leslie H Tobler, Michael P Busch, John G McHutchison, David B Goldstein, Mary Carrington, David L Thomas, Chloe L Thio, Maureen P Martin, Ying Qi, Dongliang Ge, Colm O'Huigin, Judith Kidd, Kenneth Kidd, Salim I Khakoo, Graeme Alexander, James J Goedert, Gregory D Kirk, Sharyne M Donfield, Hugo R Rosen, Leslie H Tobler, Michael P Busch, John G McHutchison, David B Goldstein, Mary Carrington

Abstract

Hepatitis C virus (HCV) infection is the most common blood-borne infection in the United States, with estimates of 4 million HCV-infected individuals in the United States and 170 million worldwide. Most (70-80%) HCV infections persist and about 30% of individuals with persistent infection develop chronic liver disease, including cirrhosis and hepatocellular carcinoma. Epidemiological, viral and host factors have been associated with the differences in HCV clearance or persistence, and studies have demonstrated that a strong host immune response against HCV favours viral clearance. Thus, variation in genes involved in the immune response may contribute to the ability to clear the virus. In a recent genome-wide association study, a single nucleotide polymorphism (rs12979860) 3 kilobases upstream of the IL28B gene, which encodes the type III interferon IFN-3, was shown to associate strongly with more than a twofold difference in response to HCV drug treatment. To determine the potential effect of rs12979860 variation on outcome to HCV infection in a natural history setting, we genotyped this variant in HCV cohorts comprised of individuals who spontaneously cleared the virus (n = 388) or had persistent infection (n = 620). We show that the C/C genotype strongly enhances resolution of HCV infection among individuals of both European and African ancestry. To our knowledge, this is the strongest and most significant genetic effect associated with natural clearance of HCV, and these results implicate a primary role for IL28B in resolution of HCV infection.

Conflict of interest statement

The authors declare no competing financial interests.

Figures

Figure 1
Figure 1
Percentage of HCV clearance by rs12979860 genotype. Data are shown for all patients, as well as whites and blacks separately.
Figure 2
Figure 2
Sampling locations, allele frequencies and degree of regional differentiation of the rs12979860 C allele. (A) The numbers identifying populations are given in Table 3. The pie charts show the frequency of the C (green) and T (blue) alleles in each population sampled. (B) Frequency distribution of FST values for 1062 SNPs from 32 of the samples grouped into six regions (Africa, Europe, South Asia, Southeast Asia, East Asia, Oceania). The red arrow indicates the position of the estimated FST for rs12979860.

References

    1. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998;47(RR-19):1–39.
    1. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35–46.
    1. Cooper S, et al. Analysis of a successful immune response against hepatitis C virus. Immunity. 1999;10(4):439–449.
    1. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5 (3):215–229.
    1. Ge D, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 In Press.
    1. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340(16):1228–1233.
    1. Thomas DL, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284(4):450–456.
    1. Thio CL. Host genetic factors and antiviral immune responses to hepatitis C virus. Clin Liver Dis. 2008;12(3):713–726. xi.
    1. Thio CL, Thomas DL, Carrington M. Chronic viral hepatitis and the human genome. Hepatology. 2000;31(4):819–827.
    1. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alpha-2b or alpha-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):24–37.
    1. Lindsay KL, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34(2):395–403.
    1. Zeuzem S, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343(23):1666–1672.
    1. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999;29(3):908–914.
    1. Goldstein DB. Common genetic variation and human traits. N Engl J Med. 2009;360(17):1696–1698.
    1. Kotenko SV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4(1):69–77.
    1. Sheppard P, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4(1):63–68.
    1. Marcello T, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006;131(6):1887–1898.
    1. Dellgren C, Gad HH, Hamming OJ, Melchjorsen J, Hartmann R. Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun. 2009;10(2):125–131.
    1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345 (1):41–52.
    1. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol. 2004;76(2):314–321.
    1. Vlahov D, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr. 1991;109:75–100.
    1. Goedert JJ, et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med. 1989;321(17):1141–1148.
    1. Hilgartner MW, et al. Hemophilia growth and development study. Design, methods, and entry data. Am J Pediatr Hematol Oncol. 1993;15(2):208–218.
    1. Osier MV, et al. ALFRED: An allele frequency database for anthropology. Am J Phys Anthropol. 2002;119(1):77–83.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera